CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Down 25.2% in February

CytoDyn Inc. (OTCMKTS:CYDYGet Free Report) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 4,724,300 shares, a drop of 25.2% from the January 31st total of 6,311,900 shares. Based on an average daily trading volume, of 5,725,000 shares, the short-interest ratio is currently 0.8 days.

CytoDyn Stock Performance

Shares of CYDY stock traded down $0.05 during mid-day trading on Friday, hitting $0.20. 8,236,298 shares of the stock were exchanged, compared to its average volume of 2,993,649. The stock’s fifty day simple moving average is $0.18 and its two-hundred day simple moving average is $0.19. The stock has a market capitalization of $200.36 million, a price-to-earnings ratio of -3.38 and a beta of 0.21. CytoDyn has a 12-month low of $0.15 and a 12-month high of $0.48.

CytoDyn (OTCMKTS:CYDYGet Free Report) last issued its quarterly earnings data on Tuesday, January 16th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

CytoDyn Company Profile

(Get Free Report)

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

Featured Stories

Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with's FREE daily email newsletter.